Syn-Ake is a cosmetic topical peptide — Dipeptide Diaminobutyroyl Benzylamide Diacetate (CAS 823202-99-9), a synthetic mimic of Waglerin-1 from the venom of the Temple Pit Viper (Tropidolaemus wagleri). It is a topical "Botox-like" anti-wrinkle ingredient (from DSM/Pentapharm) and not an injectable or systemic research peptide.
Cosmetic topical peptide; Dipeptide Diaminobutyroyl Benzylamide Diacetate, a Waglerin-1 mimetic. Single compound.
Syn-Ake mimics Waglerin-1's antagonism of the muscle-type nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction. By blocking acetylcholine-driven contraction it relaxes mimic muscles topically, softening expression lines. In vitro it reportedly blocks muscle contraction by up to about 80%, and it also shows dose-dependent antioxidant (DPPH-scavenging) activity.
Important context: the evidence is cosmetic and topical, sourced largely from the ingredient manufacturer and from in-vitro assays, not from independent clinical trials or any systemic research. There is no injection or systemic evidence base, and Syn-Ake should not be presented as comparable to studied injectable peptides.
No human clinical trial has established administration parameters for Syn-Ake; VialTalk does not provide community-sourced dosing.
A cosmetic topical with a manufacturer tolerability record; it is not a drug, and no systemic exposure is intended or characterized. Despite the "snake-venom" framing it is a synthetic, dilute cosmetic actor — not venom.
Cosmetic, manufacturer, and in-vitro data only; no systemic or independent clinical evidence.
Dipeptide Diaminobutyroyl Benzylamide Diacetate (Syn-Ake). This is a skincare ingredient; frame it as topical-cosmetic, distinct from the injectable peptide catalogue.
